Dergiler / Black Sea Journal of Health Science / 2022 / Cilt: 5 - Sayı: 2

Etiology and Histopathology of Alzheimer’s Disease and Current Approaches

Sayfa
322–327
Yayın Tarihi
2022-05-01
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Despite all these approaches for the disease, further multidisciplinary studies are needed for the definitive treatment of the disease.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Alzheimer’s disease (AD) is a widespread kind of dementia and is one of progressive neurodegenerative diseases that leads to permanent damage to neurons.
📊
Temel Bulgular & Veri:The accepted genetic factors are mutations on genetic codes especially on PSEN1, PSEN2, and APP genes.
💡
Sonuç & Katkı:Despite all these approaches for the disease, further multidisciplinary studies are needed for the definitive treatment of the disease.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alzheimer’s disease · Dementia · Beta-amyloid

Abstract

Alzheimer’s disease (AD) is a widespread kind of dementia and is one of progressive neurodegenerative diseases that leads to permanent damage to neurons. It has known that genetic and non-genetic factors play a role in the etiopathogenesis of AD. The accepted genetic factors are mutations on genetic codes especially on PSEN1, PSEN2, and APP genes. However, non-genetic factors include advanced age, exposure to occupational factors, current disorders, and lifestyle characteristics of the person. The final AD diagnosis can establish by histopathological examination of the brain after death. Pathologically, AD has two distinguishing features. Of these, beta-amyloid (Aβ) neurotic plaques are protein aggregates outside of nerve cells in the brain, whereas neurofibrillary tangles are structures found inside cells. The main component of amyloid plaques is Aβ, and the main component of neurofibrillary tangles is tau protein. Despite current therapies for Alzheimer’s disease, no definitive treatment is available. Today, preventive and curative treatment approaches for the disease include cholinesterase inhibitors, neurotrophic factors, NMDA-receptor antagonists, HMG-CoA reductase inhibitors, non-steroidal anti-inflammatory drugs, estrogen replacement therapies, antioxidants, and regular sleep. Despite all these approaches for the disease, further multidisciplinary studies are needed for the definitive treatment of the disease.

🔖

Bu Makaleye Atıf Yap

ERDEMCİ, F., AŞIR, F., TAŞ, F. (2022). Etiology and Histopathology of Alzheimer’s Disease and Current Approaches. Black Sea Journal of Health Science, Cilt: 5 - Sayı: 2, 322–327. https://ajindex.com/articles/745237

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Alzheimer A. 1907. Uber eine eigenartige Erkrankung der Hirnrinde. Allg. Zeitschrife Psychiatr, 64: 146-148.
  2. Aronson MK, Ooi WL, Geva DL, Masur D, Blau A, Frishman W. 1991. Dementia: age-dependent incidence, prevalence, and mortality in the old old. Arch Internal Medic, 151(5): 989-992.
  3. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. 2007. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet, 39: 17-23. Bolatlı G. 2021. Limbik Sistem. In: Taş F (ed) Nörobilim Alanında Multidisipliner Yaklaşımlar. İksad Publications, Ankara, Turkey, pp: 182. Breitner MD, MPH JC. 1996. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annual Rev Medic, 47(1): 401-411.
  4. Castellani RJ, Rolston RK, Smith MA. 2010. Alzheimer disease. Disease-a-month, 56(9): 484-546.
  5. Chong PL, Garic D, Shen MD, Lundgaard I, Schwichtenberg AJ. 2022. Sleep, cerebrospinal fluid, and the glymphatic system: A systematic review. Sleep Medic Rev, 61: 101572. Clark CM, Ewbank D, Lee VM-Y, Trojanowski JQ. 1998. Molecular pathology of Alzheimer’s disease: neuronal cytoskeletal abnormalities. In: Growdon JH, Rossor MN (eds) The dementias Vol 19 of Blue books of practical neurology. Butterworth–Heinemann, Boston, US, pp: 304. Ernst RL, Hay JW. 1994. The U.S. economic and social costs of Alzheimer’s disease revisited. Am J Pub Health, 84(8): 1261-1264.
  6. Fahnestock M, Garzon D, Holsinger RMD, Michalski B. 2002. Neurotrophic factors and Alzheimer’s disease: are we focusing on the wrong molecule? In Ageing and Dementia Current and Future Concepts. Springer, Vienna, Austria, pp: 252. Feng Y, Wang X. 2012. Antioxidant therapies for Alzheimer's disease. Oxidative Medic Cell Longev, 2012: 472932. Goate A, Owen M, James L, Mullan M, Rossor M, Haynes A, Hardy J. 1989. Predisposing locus for Alzheimer's disease on chromosome 21. The Lancet, 333(8634): 352-355.
  7. Graves AB, White E, Koepsell TD, Reifler BV, Van Belle G, Larson EB. 1990. The association between head trauma and Alzheimer's disease. Am J Epidemiol, 131(3): 491-501.
  8. Grundman M, Delaney P. 2002. Antioxidant strategies for Alzheimer's disease. Proc Nutri Soc, 61(2): 191-202.
  9. Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian ZS. 2018. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain, 141(7): 1917-1933.
  10. Helmer C, Joly P, Letenneur L, Commenges D, Dartigues JF. 2001. Mortality with dementia: